Even High Doses of Gadolinium-Based Contrast Agents Doesn't Cause NSF
July 1, 2009 - High doses, gadolinium-based contrast agents alone are not sufficient to cause nephrogenic systemic fibrosis (NSF) in patients with kidney problems, according to a study performed at the Mayo Clinic Florida, Jacksonville, FL.
Contrary to other research indicating NSF is caused by gadolinium-based contrast agents that are commonly used today during MR procedures, this new study, which is published in the June issue of the American Journal of Roentgenology, found contradicting evidence.
The study examined the records of 61 patients who had been given high doses - from two to ten times the usual MRI dose. The patients were undergoing interventional procedures before there were any reports linking gadolinium to NSF. Just one of these patients, a 58-year-old diabetic man with end-stage kidney disease and significant blood vessel blockages, developed NSF.
The researchers concluded: “Although gadolinium exposure appears to be a necessary precondition for NSF, gadolinium-based contrast agents alone are not sufficient to cause the disorder, even in very high doses. Clinically relevant nephrotoxicity of gadolinium-based contrast agents was not found.”
For more information: www.ajronline.org
Feedback Welcome... Imaging Technology News welcomes your thoughts/comments.
eMail: itneditor@sgcmail.com
Mail: Editor, Imaging Technology News, Scranton Gillette Communications, Inc., 3030 W. Salt Creek Lane, Suite 201, Arlington Heights, IL 60005-5025




